Identification of Genetic Variants Using Next-Generation Sequencing in Pediatric Myelodysplastic Syndrome: From Disease Biology to Clinical Applications
- PMID: 40725152
- PMCID: PMC12294961
- DOI: 10.3390/ijms26146907
Identification of Genetic Variants Using Next-Generation Sequencing in Pediatric Myelodysplastic Syndrome: From Disease Biology to Clinical Applications
Abstract
This study aimed to identify genetic variants using a customized next-generation sequencing (NGS) panel for pediatric myelodysplastic syndrome (pMDS) and to explore their associations with cytogenetic and clinical characteristics. Cytogenetic analyses were conducted using G-banding and fluorescence in situ hybridization. NGS was performed with the Ion Torrent Personal Genome Machine for the following genes: GATA2, RUNX1, CEBPA, ANKRD26, ETV6, SAMD9, SAMD9L, PTPN11, NRAS, SETBP1, DDX41, TP53, FLT3, SRP72, and JAK3. Analyses were performed with Ion Reporter 5.20.8.0 software. Genetic variants were classified using the dbSNP, 1000 Genomes, COSMIC, and Varsome databases. We analyzed 25 cases of pMDS; 15 presented abnormal karyotypes, and 19 showed genetic variants. Among the 29 variants identified across 12/15 genes, 27% were pathogenic and 14% were likely pathogenic, with NRAS and GATA2 most frequently associated with disease progression. A new somatic variant of uncertain significance in SETBP1 was detected in seven patients showing heterogeneous clinical outcomes. Genetic variants were found in 7/10 patients with normal karyotypes, indicating that submicroscopic alterations can shed light on disease biology. Our results highlight the critical role of a targeted NGS panel in identifying molecular alterations associated with pMDS pathogenesis, thereby enhancing diagnostic precision, prognosis, and aiding in treatment selection.
Keywords: genetic variants; pediatric myelodysplastic syndrome; targeted NGS panel.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.J Cancer Res Clin Oncol. 2022 Jan;148(1):107-119. doi: 10.1007/s00432-021-03813-1. Epub 2021 Oct 9. J Cancer Res Clin Oncol. 2022. PMID: 34626238 Free PMC article.
-
Germline and somatic genetic landscape of pediatric myelodysplastic syndromes.Haematologica. 2025 Sep 1;110(9):1974-1986. doi: 10.3324/haematol.2024.285700. Epub 2025 Jun 26. Haematologica. 2025. PMID: 40568716 Free PMC article. Review.
-
Screening of premature ovarian insufficiency associated genes in Hungarian patients with next generation sequencing.BMC Med Genomics. 2024 Apr 22;17(1):98. doi: 10.1186/s12920-024-01873-z. BMC Med Genomics. 2024. PMID: 38649916 Free PMC article.
-
Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study.Clin Cancer Res. 2025 Jul 15;31(14):3062-3071. doi: 10.1158/1078-0432.CCR-24-4251. Clin Cancer Res. 2025. PMID: 40388595 Free PMC article.
-
Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations.J Biomed Sci. 2018 Jun 2;25(1):51. doi: 10.1186/s12929-018-0442-4. J Biomed Sci. 2018. PMID: 29859540 Free PMC article.
References
-
- Arber D.A., Orazi A., Hasserjian R.P., Borowitz M.J., Calvo K.R., Kvasnicka H.-M., Wang S.A., Bagg A., Barbui T., Branford S., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. doi: 10.1182/blood.2022015850. - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous